Results 251 to 260 of about 26,068 (276)

Finerenone: A Novel Third-Generation Mineralocorticoid Receptor Antagonist

Cardiology in Review, 2023
Finerenone is a novel third-generation, selective nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved by the Food and Drug Administration in July of 2021 for its use in adults with chronic kidney disease and Type II diabetes mellitus.
Paola, Gudino Flores, Juan Diego, Rodriguez Salazar, Bryan Lester, Nahar, Belinda, Jim   +3 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists (MRAs)

Abstract The final process in the renin–angiotensin–aldosterone system (RAAS) is the production of the mineralocorticoid aldosterone in the adrenal glands. Aldosterone has an important role in the pathophysiology of heart failure, and concentrations of aldosterone are 20-fold higher in patients with HF compared to normal individuals ...
Roy S. Gardner, Theresa A. McDonagh, Daniel J. Doherty, Nikki L. Walker   +3 more
openaire   +1 more source

Recent Advances in Mineralocorticoid Receptor Antagonists

2011
Publisher Summary This chapter focuses on recent advances in mineralocorticoid receptor (MR) antagonists. MR is a member of the nuclear hormone receptor superfamily and is structurally related to the progesterone receptor, androgen receptor, estrogen receptor, and glucocorticoid receptor.
Katerina Leftheris, Yajun Zheng, Deepak S. Lala   +2 more
openaire   +1 more source

Mineralocorticoid receptor antagonists and endothelial function.

Current opinion in investigational drugs (London, England : 2000), 2008
Hyperaldosteronism is associated with endothelial dysfunction and impaired vascular reactivity in patients with hypertension or congestive heart failure. When present, endothelial dysfunction is an independent predictor of adverse cardiovascular events.
Bradley A, Maron, Jane A, Leopold
openaire   +1 more source

Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes

Kidney International Supplements, 2022
Peter R Rossing
exaly  

Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms

Kidney International Supplements, 2022
Johann Bauersachs, Achim Lother
exaly  

Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects

Nature Reviews Nephrology, 2021
Jonatan Barrera-Chimal, Ixchel Lima Posada, George Bakris   +2 more
exaly  

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

European Heart Journal, 2021
Rajiv Agarwal, Peter Kolkhof, George Bakris   +2 more
exaly  

The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis

Kidney International Supplements, 2022
James M Luther
exaly  

Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists—unmet needs and underserved patient cohorts

Kidney International Supplements, 2022
Murray Epstein
exaly